More context, better questions

Semaglutide is a GLP-1 receptor agonist available in multiple prescription products. Ozempic, Wegovy, and Rybelsus are familiar brand names, but they should not be treated as interchangeable instructions. Different formulations and strengths have different labels, approved uses, administration requirements, and patient populations.

Tirzepatide is a prescription peptide that activates two incretin receptors, GIP and GLP-1. In the United States, approved products include Mounjaro and Zepbound. Those brands have different labeled uses, so the ingredient name alone does not identify the indication, eligibility criteria, presentation, or insurance coverage.

The peptide mimics selected actions of the intestinal hormone GLP-1. Its effects include glucose-dependent insulin secretion, changes in glucagon release, slower gastric emptying, and reduced appetite. Formulation matters because absorption after swallowing a medicine differs from absorption after injection. Milligram numbers therefore cannot be compared casually across presentations or across different drugs.

GIP and GLP-1 are signals involved in the response to food. Tirzepatide engages both receptor systems and changes glucose-dependent insulin secretion, glucagon signaling, appetite, and gastric emptying. A receptor diagram explains the biological targets; it cannot predict how much weight an individual will lose or which adverse effects that person will experience.

Randomized studies support specific clinical uses of approved semaglutide products. Assess the endpoint being discussed: HbA1c, body weight, cardiovascular events, or another disease outcome. A result from one indication does not automatically establish every proposed use. Regulatory labeling has evolved, including newer presentations and strengths, so an old dosing chart may be incomplete.

Large randomized clinical programs have evaluated blood-glucose control and weight management. Evidence should be interpreted separately for people with and without diabetes and for each comparator, follow-up period, and dose. Weight loss is a study outcome, while cardiovascular events, sleep-apnea outcomes, treatment persistence, and quality of life are distinct questions with their own evidence.

This overview does not rank all current semaglutide presentations or reproduce every indication. Trial averages hide variation in response and discontinuation. Claims that every person will achieve the headline percentage, or that a compound is equivalent because its name resembles semaglutide, go beyond the evidence. Verify the exact product and current label with the prescriber.

An average change in a trial is not a guaranteed personal result. Cross-trial comparisons can mislead when participants, background care, doses, and statistical methods differ. Findings from an approved manufactured product also do not validate an online vial bearing the same ingredient name. Read the current product label for the population and use that apply.

Gastrointestinal effects are common. Relevant labels include important warnings and contraindications, including medullary thyroid carcinoma or MEN2 history. Discuss other glucose-lowering medicines, pregnancy plans, severe gastrointestinal disease, dehydration, and relevant eye disease with a clinician. Storage and administration errors can create additional risks independent of the pharmacology.

Common adverse effects include gastrointestinal symptoms. Product labeling addresses serious risks and contraindications, including medullary thyroid carcinoma or MEN2 history. Pancreatitis, gallbladder symptoms, dehydration, interactions with other glucose-lowering medicines, and pregnancy planning require clinician discussion. Persistent severe abdominal pain, allergic symptoms, or an inability to keep fluids down warrant prompt medical assessment.

FDA-approved semaglutide medicines are available in the United States. FDA has separately warned about unapproved versions and salt forms. Compounded products are not FDA approved, and a research-use label is not evidence of treatment quality.

FDA-approved prescription products exist. Approval is product-specific and does not extend to every compounded or research-labeled version. FDA has warned about unapproved GLP-1 products marketed directly to consumers.